Business
SeeThruEquity Initiates Coverage on Sernova Corp. (TSX: SVA, OTCQB: SEOVF) with a Price Target of CAD $0.76
NEW YORK, NY / ACCESSWIRE / October 5, 2015 / SeeThruEquity, a leading independent equity re...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"SeeThruEquity Initiates Coverage on Sernova Corp. (TSX: SVA, OTCQB: SEOVF) with a Price Target of CAD $0.76NEW YORK, NY / ACCESSWIRE / October 5, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it recently initiated coverage of Sernova Corp. (TSX: SVA, OTCQB: SEOVF) with a Price Target of CAD $0.76.\nThe report is available here: SVA Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.\nWith headquarters in London, Ontario, Sernova is a clinical stage medical company focused on developing disruptive platform technologies that use regenerative medicine to treat chronic diseases. Initially Sernova is developing medical technologies aimed at treating chronic metabolic diseases including Type 1 and Type 2 diabetes, blood disorders such as hemophilia, thyroid disease, and other diseases. We see several potential catalysts ahead for the company as it pursues a partner-based strategy for advancing its clinical development program - and ultimately commercialization – for the treatment of the approximately 30mn people worldwide who suffer from insulin-dependent diabetes.\n\"The company's patented Cell Pouch System(TM) is a novel, implantable medical device technology for delivering therapeutic cells in a safe and biologically appropriate environment,\" stated Ajay Tandon, CEO of SeeThruEquity. \"We find the technology to be compelling, especially in light of the large market opportunity as 30 million people worldwide suffer from insulin-dependent diabetes. We are initiating coverage with a 12-month price target of CAD$0.76 per share.\"\nAdditional highlights from the report are as follows:\nCell Pouch System(TM) offers a novel approach to diabetes treatment\nSernova's Cell Pouch System(TM) is a subcutaneous implantable medical device technology that is designed for the transplantation of therapeutic cells, including donor, xenogeneic, or stem cell derived therapeutic cells to treat chronic diseases. The Cell Pouch System(TM) was custom designed to provide a natural environment for therapeutic ce...